Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis as a diagnostic tool: A systematic review

Mauch, Renan Marrichi; Levy, Carlos Emílio

doi:10.1016/j.jcf.2014.01.005

Cited by 40 publications

(47 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The chronic P. aeruginosa biofilm lung infection leads to a pronounced IgG antibody (15). response against P. aeruginosa components including alginate, and these specific antibodies can be detected in blood and used diagnostically (5,6,(16)(17)(18)(19)(20) (Tables 1-2) (Fig. 3A).…”

Section: Cystic Fibrosis and Biofilm Infection -Pathogenetic And Diagmentioning

confidence: 99%

Diagnosis of biofilm infections in cystic fibrosis patients

Høiby

Bjarnsholt

Moser

et al. 2017

APMIS

View full text Add to dashboard Cite

Chronic Pseudomonas aeruginosa biofilm lung infection in cystic fibrosis patients is the best described biofilm infection in medicine. The initial focus can be the paranasal sinuses and then follows repeated colonization and infection of the lungs by aspiration. The matrix of the biofilms is dominated by alginate and the pathogenesis of tissue damage is immune complex‐mediated chronic inflammation dominated by polymorphonuclear leukocytes and their products (DNA, oxygen radicals and proteases). The P. aeruginosa biofilm infection can be diagnosed by microscopy of lung tissue, sputum and mucus from the paranasal sinuses, where aggregates of the bacteria are found surrounded by the abundant alginate matrix. Specific PNA‐FISH probes can be used to identify P. aeruginosa and other pathogens in situ in the biofilms. Growth of mucoid colonies from the locations mentioned above is also diagnostic for biofilm infection. Rise of specific anti‐P. aeruginosa antibodies is likewise diagnostic, IgG in serum in case of lung infection, sIgA in saliva or nasal secretions in case of paranasal sinus infection. Similar approaches have been developed to diagnose chronic biofilm infections in cystic fibrosis caused by other pathogens e.g., Stenotrophomonas, Burkholderia multivorans, Achromobacter xylosoxidans and Mycobacterium abscessus complex.

show abstract

Section: Cystic Fibrosis and Biofilm Infection -Pathogenetic And Diagmentioning

confidence: 99%

Diagnosis of biofilm infections in cystic fibrosis patients

Høiby

Bjarnsholt

Moser

et al. 2017

APMIS

View full text Add to dashboard Cite

show abstract

“…P. aeruginosa serology has proved a useful clinical tool in supporting clinical decision making [15,[17][18][19]. The principle has limitations [20,21], and treatment decisions should not be based on P. aeruginosa antibody levels alone, since the antibody response to some antigens may be delayed [17].…”

Section: Usefulness Of Risk Algorithmmentioning

confidence: 99%

“…Patients with CF are followed closely for their entire lives and there might be a benefit in using serodiagnosis as a complement to routine culture, in the same way that antibodies against Pseudomonas aeruginosa and Aspergillus are used successfully in many CF centres [15][16][17][18][19]. Limitations in the predictive values of such assays have been reported [20], and currently antibody measurements for P. aeruginosa are used clinically in combination with culture results, rather than as stand-alone tests [21].…”

Section: Introductionmentioning

confidence: 99%

Serodiagnosis ofMycobacterium abscessuscomplex infection in cystic fibrosis

et al. 2015

View full text Add to dashboard Cite

Early signs of pulmonary disease with Mycobacterium abscessus complex (MABSC) can be missed in patients with cystic fibrosis (CF). A serological method could help stratify patients according to risk. The objective of this study was to test the diagnostic accuracy of a novel method for investigating IgG activity against MABSC.A prospective study of all patients attending the Copenhagen CF Centre was conducted by culturing for MABSC during a 22-month period and then screening patients with an anti-MABSC IgG ELISA. Culturepositive patients had stored serum examined for antibody kinetics before and after culture conversion.307 patients had 3480 respiratory samples cultured and were then tested with the anti-MABSC IgG ELISA. Patients with MABSC pulmonary disease had median anti-MABSC IgG levels six-fold higher than patients with no history of infection (434 versus 64 ELISA units; p<0.001). The test sensitivity was 95% (95% CI 74-99%) and the specificity was 73% (95% CI 67-78%). A diagnostic algorithm was constructed to stratify patients according to risk.The test accurately identified patients with pulmonary disease caused by MABSC and was suited to be used as a complement to mycobacterial culture. @ERSpublications Measuring antibodies against Mycobacterium abscessus can identify patients who harbour this emerging threat to health

show abstract

“…An example of ancillary methods is the detection of serum antibodies against P . aeruginosa ; however, its use in clinical practice remains controversial [35]. In this study, anti-PaAb showed a positive correlation with sCD40L levels, suggesting that its fluctuation reliably reflects the clinical status of infection by this bacterium.…”

Section: Discussionmentioning

confidence: 63%

A High Level of Soluble CD40L Is Associated with P. aeruginosa Infection in Patients with Cystic Fibrosis

et al. 2016

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to evaluate whether the concentration of sCD40L, a product of platelet activation, correlates with the presence of Pseudomonas aeruginosa in the airway of patients with cystic fibrosis (CF) and to determine its possible clinical association.MethodsSixty patients with CF, ranging in age from 2 months to 36 years, were studied. The demographics, cystic fibrosis transmembrane conductance regulator (CFTR) genotype, spirometry measurements, radiographic and tomographic scans, platelet count in peripheral blood, sCD40L, IL-6, TNF-α and ICAM1 data were collected. Infection-colonization of the airway was evaluated using sputum and throat swab cultures; the levels of anti-Pseudomonas aeruginosa antibodies (Anti-PaAb) were evaluated.ResultsPatients with CF and chronic colonization had anti-PaAb values of 11.6 ± 2.1 ELISA units (EU) and sCD40L in plasma of 1530.9 ±1162.3 pg/mL; those with intermittent infection had 5.7 ± 2.7 EU and 2243.6 ± 1475.9 pg/mL; and those who were never infected had 3.46 ± 1.8 EU (p≤0.001) and 1008.1 ± 746.8 pg/mL (p≤0.01), respectively. The cutoff value of sCD40L of 1255 pg/mL was associated with an area under the ROC (receiver operating characteristic curve) of 0.84 (95% CI, 0.71 to 0.97), reflecting P. aeruginosa infection with a sensitivity of 73% and a specificity of 89%. Lung damage was determined using the Brasfield Score, the Bhalla Score, and spirometry (FVC%, FEV1%) and found to be significantly different among the groups (p≤0.001).ConclusionCirculating sCD40L levels are increased in patients with cystic fibrosis and P. aeruginosa infection. Soluble CD40L appears to reflect infection and provides a tool for monitoring the evolution of lung deterioration.

show abstract

Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis as a diagnostic tool: A systematic review

Abstract: The detection of serum antibodies to P. aeruginosa shows capacity for early detection of this pathogen and potential utility and viability of incorporation in the diagnostic routine of patients with cystic fibrosis.

Cited by 40 publications

References 41 publications

Diagnosis of biofilm infections in cystic fibrosis patients

Diagnosis of biofilm infections in cystic fibrosis patients

Serodiagnosis ofMycobacterium abscessuscomplex infection in cystic fibrosis

A High Level of Soluble CD40L Is Associated with P. aeruginosa Infection in Patients with Cystic Fibrosis

Contact Info

Product

Resources

About